Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1-2
pubmed:dateCreated
2007-6-11
pubmed:abstractText
Angiogenic therapies may need to select a stable agent to be delivered. In the study, a nonpeptide angiogenic agent, ginsenoside Rg(1) (Rg(1)), was encapsulated in the gelatin microspheres (MSs) crosslinked with genipin and intramuscularly injected into a rat model with infarcted myocardium. bFGF was used as a control. After swelling in an aqueous environment, the MSs without crosslinking became collapsed and stuck together. For those crosslinked, the swollen MSs appeared to be more stable with an increasing the degree of crosslinking. After it was released from MSs in vitro, the remaining activity of bFGF on HUVEC proliferation reduced significantly, while that of Rg(1) remained constant. An inspection of the retrieved hearts revealed a large aneurysmal left ventricle (LV) with a thinned myocardium and a significant myocardial fibrosis for that treated with the Empty MSs (without drug encapsulation). However, those receiving the MSs encapsulated with bFGF or Rg(1) attenuated the enlargement of the LV cavity and the development of myocardial fibrosis. The densities of microvessels found in the border zones of the infarct treated with the bFGF or Rg(1) MSs were significantly greater than that treated with the Empty MSs. These results indicated that Rg(1), a stable angiogenic agent, successfully enhanced the myocardial perfusion and preserved the infarcted LV function.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1873-4995
pubmed:author
pubmed:issnType
Electronic
pubmed:day
16
pubmed:volume
120
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
27-34
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17532519-Angiogenesis Inducing Agents, pubmed-meshheading:17532519-Animals, pubmed-meshheading:17532519-Cell Proliferation, pubmed-meshheading:17532519-Cells, Cultured, pubmed-meshheading:17532519-Chemistry, Pharmaceutical, pubmed-meshheading:17532519-Coronary Circulation, pubmed-meshheading:17532519-Cross-Linking Reagents, pubmed-meshheading:17532519-Disease Models, Animal, pubmed-meshheading:17532519-Drug Carriers, pubmed-meshheading:17532519-Drug Compounding, pubmed-meshheading:17532519-Endothelial Cells, pubmed-meshheading:17532519-Feasibility Studies, pubmed-meshheading:17532519-Fibroblast Growth Factor 2, pubmed-meshheading:17532519-Fibrosis, pubmed-meshheading:17532519-Gelatin, pubmed-meshheading:17532519-Ginsenosides, pubmed-meshheading:17532519-Humans, pubmed-meshheading:17532519-Injections, Intramuscular, pubmed-meshheading:17532519-Iridoid Glycosides, pubmed-meshheading:17532519-Iridoids, pubmed-meshheading:17532519-Male, pubmed-meshheading:17532519-Microspheres, pubmed-meshheading:17532519-Myocardial Infarction, pubmed-meshheading:17532519-Neovascularization, Physiologic, pubmed-meshheading:17532519-Particle Size, pubmed-meshheading:17532519-Rats, pubmed-meshheading:17532519-Rats, Sprague-Dawley, pubmed-meshheading:17532519-Solubility, pubmed-meshheading:17532519-Time Factors, pubmed-meshheading:17532519-Ventricular Function, Left, pubmed-meshheading:17532519-Ventricular Remodeling
pubmed:year
2007
pubmed:articleTitle
Gelatin microspheres encapsulated with a nonpeptide angiogenic agent, ginsenoside Rg1, for intramyocardial injection in a rat model with infarcted myocardium.
pubmed:affiliation
Division of Cardiovascular Surgery, Veterans General Hospital-Taichung, and College of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't